全文获取类型
收费全文 | 1293713篇 |
免费 | 96909篇 |
国内免费 | 3538篇 |
专业分类
耳鼻咽喉 | 18378篇 |
儿科学 | 42470篇 |
妇产科学 | 37998篇 |
基础医学 | 188823篇 |
口腔科学 | 35780篇 |
临床医学 | 110478篇 |
内科学 | 253440篇 |
皮肤病学 | 26684篇 |
神经病学 | 99935篇 |
特种医学 | 50678篇 |
外国民族医学 | 376篇 |
外科学 | 199272篇 |
综合类 | 31217篇 |
现状与发展 | 8篇 |
一般理论 | 300篇 |
预防医学 | 94302篇 |
眼科学 | 29612篇 |
药学 | 100032篇 |
20篇 | |
中国医学 | 4294篇 |
肿瘤学 | 70063篇 |
出版年
2018年 | 12529篇 |
2016年 | 10719篇 |
2015年 | 12590篇 |
2014年 | 17241篇 |
2013年 | 25494篇 |
2012年 | 35100篇 |
2011年 | 37624篇 |
2010年 | 22393篇 |
2009年 | 20958篇 |
2008年 | 36117篇 |
2007年 | 38947篇 |
2006年 | 39495篇 |
2005年 | 38598篇 |
2004年 | 37054篇 |
2003年 | 36187篇 |
2002年 | 35617篇 |
2001年 | 58630篇 |
2000年 | 59979篇 |
1999年 | 50943篇 |
1998年 | 14369篇 |
1997年 | 12971篇 |
1996年 | 13190篇 |
1995年 | 12450篇 |
1994年 | 11851篇 |
1993年 | 10910篇 |
1992年 | 41037篇 |
1991年 | 40405篇 |
1990年 | 39914篇 |
1989年 | 38738篇 |
1988年 | 36133篇 |
1987年 | 35369篇 |
1986年 | 33743篇 |
1985年 | 32150篇 |
1984年 | 23927篇 |
1983年 | 20821篇 |
1982年 | 12381篇 |
1981年 | 10934篇 |
1979年 | 22637篇 |
1978年 | 15877篇 |
1977年 | 13729篇 |
1976年 | 12970篇 |
1975年 | 14201篇 |
1974年 | 16682篇 |
1973年 | 16076篇 |
1972年 | 15318篇 |
1971年 | 14229篇 |
1970年 | 13214篇 |
1969年 | 12731篇 |
1968年 | 11978篇 |
1967年 | 10478篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 鉴定当地民间应用普遍的野生药用真菌,并探讨其治疗肿瘤的作用机制。方法 采用形态学和分子生物学方法对一株采自定陶仿山野生药用真菌进行鉴定,确定为硬皮马勃。通过文献检索收集硬皮马勃化学成分,利用PubChem软件和TCMSP、GCS数据库得到化学成分结构信息及其药用动力学参数和相关靶点分析,通过SysDT和WES系统鉴定潜在化学成分靶点,利用CTD数据库获得靶点功能,将潜在化合物和肿瘤相关靶点导入Cytoscape3.8.0软件构建分子-靶标网络。应用DAVID数据库对肿瘤相关靶点进行GO和KEGG富集分析,揭示有关活性成分靶点所涉及的生物学过程和通路,将肿瘤相关靶点和通路导入Cytoscape3.8.0软件构建靶点-通路网络。结果 从文献中获得硬皮马勃的化学成分59个,通过ADME计算系统筛选出5个潜在活性的化合物即活性成分,预测到38个靶点,其中与肿瘤相关靶点16个。这些活性成分主要通过Toll-like receptor、PI3K-AKT、MAPK和NF-kappa B等通路参与免疫应答,抑制肿瘤细胞生长、增殖,促进其凋亡。结论 表明硬皮马勃治疗肿瘤具有多靶点、多途径协同作用的特点,并通过多层次效应达到治疗肿瘤的效果。本研究为更好理解硬皮马勃作用肿瘤的机制和肿瘤药物开发提供理论依据。 相似文献
2.
3.
4.
5.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
6.
7.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
8.
9.
Platelets are needed to prevent or arrest bleeding and aggregate at the site of injury upon vascular damage. Platelets express receptors for estrogens which might affect the function of the platelets and their hemostatic ability. The aim was to identify possible differences in platelet function related to age, gender, and phases of the menstrual cycle by use of impedance aggregometry with Multiplate. In the first part of the study, platelet function was assessed in 60 healthy individuals (30 men and 30 women) in each of three age groups (20–25, 40–45, and 60–65 years). In the second part of the study, the platelet function was analyzed on four occasions during the menstrual cycle in women without oral contraceptives (OCs) (n = 17) and compared to 19 women on OCs and 18 men of similar age (20–40 years). For the women on OCs, aggregation was analyzed once during the tablet-free week and once late during the period with OCs. The men were sampled once. Women of younger age (<45 years) had significantly higher agonist-induced aggregation response than both men and post-menopausal women (60–65 years). The agonist-induced aggregation response did not differ between phases of the menstrual cycle or OC use. The results suggest that estradiol and/or progesterone affect spontaneous aggregation since it was found to be lowest in the mid-luteal phase. Spontaneous aggregation was significantly lower in women on OCs than in both men and women without OCs. Our findings indicate that fertile age is associated with higher aggregation response capacity of the platelets, possibly to prevent excessive bleeding during menstruation, but this response capacity is not altered during the menstrual cycle or by use of OCs. 相似文献
10.